217 related articles for article (PubMed ID: 24568837)
1. Variability in phenylalanine control predicts IQ and executive abilities in children with phenylketonuria.
Hood A; Grange DK; Christ SE; Steiner R; White DA
Mol Genet Metab; 2014 Apr; 111(4):445-51. PubMed ID: 24568837
[TBL] [Abstract][Full Text] [Related]
2. Stability of blood phenylalanine levels and IQ in children with phenylketonuria.
Anastasoaie V; Kurzius L; Forbes P; Waisbren S
Mol Genet Metab; 2008; 95(1-2):17-20. PubMed ID: 18703366
[TBL] [Abstract][Full Text] [Related]
3. Prolonged exposure to high and variable phenylalanine levels over the lifetime predicts brain white matter integrity in children with phenylketonuria.
Hood A; Antenor-Dorsey JA; Rutlin J; Hershey T; Shimony JS; McKinstry RC; Grange DK; Christ SE; Steiner R; White DA
Mol Genet Metab; 2015 Jan; 114(1):19-24. PubMed ID: 25481106
[TBL] [Abstract][Full Text] [Related]
4. Neurocognitive functioning in adults with phenylketonuria: results of a long term study.
Weglage J; Fromm J; van Teeffelen-Heithoff A; Möller HE; Koletzko B; Marquardt T; Rutsch F; Feldmann R
Mol Genet Metab; 2013; 110 Suppl():S44-8. PubMed ID: 24071437
[TBL] [Abstract][Full Text] [Related]
5. The impact of phenylalanine levels on cognitive outcomes in adults with phenylketonuria: Effects across tasks and developmental stages.
Romani C; Palermo L; MacDonald A; Limback E; Hall SK; Geberhiwot T
Neuropsychology; 2017 Mar; 31(3):242-254. PubMed ID: 28240926
[TBL] [Abstract][Full Text] [Related]
6. Cognitive profile and mental health in adult phenylketonuria: A PKU-COBESO study.
Jahja R; Huijbregts SCJ; de Sonneville LMJ; van der Meere JJ; Legemaat AM; Bosch AM; Hollak CEM; Rubio-Gozalbo ME; Brouwers MCGJ; Hofstede FC; de Vries MC; Janssen MCH; van der Ploeg AT; Langendonk JG; van Spronsen FJ
Neuropsychology; 2017 May; 31(4):437-447. PubMed ID: 28318283
[TBL] [Abstract][Full Text] [Related]
7. White matter integrity and executive abilities in individuals with phenylketonuria.
Antenor-Dorsey JA; Hershey T; Rutlin J; Shimony JS; McKinstry RC; Grange DK; Christ SE; White DA
Mol Genet Metab; 2013 Jun; 109(2):125-31. PubMed ID: 23608077
[TBL] [Abstract][Full Text] [Related]
8. Children and Adolescents with Early Treated Phenylketonuria: Cognitive Development and Fluctuations of Blood Phenylalanine Levels.
Feldmann R; Och U; Beckmann LS; Weglage J; Rutsch F
Int J Environ Res Public Health; 2024 Apr; 21(4):. PubMed ID: 38673342
[TBL] [Abstract][Full Text] [Related]
9. Intellectual development of the patients of the German Collaborative Study of children treated for phenylketonuria.
Burgard P; Schmidt E; Rupp A; Schneider W; Bremer HJ
Eur J Pediatr; 1996 Jul; 155 Suppl 1():S33-8. PubMed ID: 8828606
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine monitoring in children with early and continuously treated phenylketonuria: results of an international practice survey.
Sharman R; Sullivan KA; Young RM; McGill JJ
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S417-20. PubMed ID: 20882350
[TBL] [Abstract][Full Text] [Related]
11. Mental health and social functioning in early treated Phenylketonuria: the PKU-COBESO study.
Jahja R; Huijbregts SC; de Sonneville LM; van der Meere JJ; Bosch AM; Hollak CE; Rubio-Gozalbo ME; Brouwers MC; Hofstede FC; de Vries MC; Janssen MC; van der Ploeg AT; Langendonk JG; van Spronsen FJ
Mol Genet Metab; 2013; 110 Suppl():S57-61. PubMed ID: 24183792
[TBL] [Abstract][Full Text] [Related]
12. Impact of the phenylalanine hydroxylase gene on maternal phenylketonuria outcome.
Güttler F; Azen C; Guldberg P; Romstad A; Hanley WB; Levy HL; Matalon R; Rouse BM; Trefz F; de la Cruz F; Koch R
Pediatrics; 2003 Dec; 112(6 Pt 2):1530-3. PubMed ID: 14654659
[TBL] [Abstract][Full Text] [Related]
13. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis.
Waisbren SE; Noel K; Fahrbach K; Cella C; Frame D; Dorenbaum A; Levy H
Mol Genet Metab; 2007; 92(1-2):63-70. PubMed ID: 17591452
[TBL] [Abstract][Full Text] [Related]
14. Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria.
Viau KS; Wengreen HJ; Ernst SL; Cantor NL; Furtado LV; Longo N
J Inherit Metab Dis; 2011 Aug; 34(4):963-71. PubMed ID: 21556836
[TBL] [Abstract][Full Text] [Related]
15. Executive functioning in children and adolescents with phenylketonuria.
VanZutphen K; Packman W; Sporri L; Needham M; Morgan C; Weisiger K; Packman S
Clin Genet; 2007 Jul; 72(1):13-8. PubMed ID: 17594394
[TBL] [Abstract][Full Text] [Related]
16. A preliminary investigation of the role of the phenylalanine:tyrosine ratio in children with early and continuously treated phenylketonuria: toward identification of "safe" levels.
Sharman R; Sullivan K; Young R; McGill J
Dev Neuropsychol; 2010; 35(1):57-65. PubMed ID: 20390592
[TBL] [Abstract][Full Text] [Related]
17. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU.
Diamond A; Prevor MB; Callender G; Druin DP
Monogr Soc Res Child Dev; 1997; 62(4):i-v, 1-208. PubMed ID: 9421921
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of hyperphenylalaninemia and intellectual outcome in teenagers with phenylketonuria.
Didycz B; Bik-Multanowski M
Acta Biochim Pol; 2017; 64(3):527-531. PubMed ID: 28850634
[TBL] [Abstract][Full Text] [Related]
19. Processing speed and executive abilities in children with phenylketonuria.
Janos AL; Grange DK; Steiner RD; White DA
Neuropsychology; 2012 Nov; 26(6):735-43. PubMed ID: 22866986
[TBL] [Abstract][Full Text] [Related]
20. Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations.
Huijbregts SC; de Sonneville LM; Licht R; van Spronsen FJ; Verkerk PH; Sergeant JA
Neuropsychologia; 2002; 40(1):7-15. PubMed ID: 11595258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
